Iconic Therapeutics is a leading brand that focuses on pioneering a new class of therapeutics by harnessing their in-depth understanding of tissue factor (TF) biology. As a wholly owned subsidiary of Endpoint Health, Iconic Therapeutics is committed to revolutionizing healthcare. Their expertise lies in various areas, including ophthalmology, oncology, and inflammation.

In the field of inflammation, Iconic Therapeutics recognizes TF as an ideal target for treating acute and chronic inflammatory conditions, such as acute lung injury, vasculitis, anti-phospholipid syndrome, and inflammatory bowel disease. In ophthalmology, they see promising opportunities to address serious diseases like age-related macular degeneration (AMD) and diabetic retinopathy. Furthermore, Iconic Therapeutics focuses on TF in oncology, where its overexpression facilitates key oncogenic processes that contribute to tumor development and progression.

Notably, their oncology program is partnered with Exelixis. With a notable track record of achievements and collaborations, Iconic Therapeutics continues to make significant strides in the medical field. Stay informed about their latest breakthroughs and advancements by visiting their newsroom and accessing their publications